These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 27729659

  • 1. Biosimilars in IBD: from theory to practice.
    Danese S, Bonovas S, Peyrin-Biroulet L.
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biosimilars in ulcerative colitis: When and for who?
    Ilias A, Gonczi L, Kurti Z, Lakatos PL.
    Best Pract Res Clin Gastroenterol; 2018 Jan; 32-33():35-42. PubMed ID: 30060937
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 7. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P, Fiorino G, Danese S.
    Curr Pharm Des; 2017 Jun; 23(44):6759-6769. PubMed ID: 29205114
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Bhat S, Limdi JK, Cross RK, Farraye FA.
    Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biosimilars in Dermatology: Current Situation (Part I).
    Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M, en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.
    Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
    [Abstract] [Full Text] [Related]

  • 12. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S, Gabbani T, Annese V.
    World J Gastroenterol; 2017 Jan 14; 23(2):197-203. PubMed ID: 28127193
    [Abstract] [Full Text] [Related]

  • 15. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L, Ilias A, Kurti Z, Lakatos PL.
    Curr Pharm Des; 2019 Jan 14; 25(1):13-18. PubMed ID: 30864504
    [Abstract] [Full Text] [Related]

  • 16. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M, Sciascia S, Roccatello D, Cuadrado MJ.
    BioDrugs; 2017 Feb 14; 31(1):37-49. PubMed ID: 28035633
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNFs: Originators and Biosimilars.
    Mantzaris GJ.
    Dig Dis; 2016 Feb 14; 34(1-2):132-9. PubMed ID: 26983015
    [Abstract] [Full Text] [Related]

  • 18. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M, en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.
    Actas Dermosifiliogr; 2015 Sep 14; 106(7):550-4. PubMed ID: 26049964
    [Abstract] [Full Text] [Related]

  • 19. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G, Danese S.
    Best Pract Res Clin Gastroenterol; 2014 Jun 14; 28(3):465-71. PubMed ID: 24913385
    [Abstract] [Full Text] [Related]

  • 20. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
    Danese S, Gomollon F, Governing Board and Operational Board of ECCO.
    J Crohns Colitis; 2013 Aug 14; 7(7):586-9. PubMed ID: 23623738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.